| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Revenues | 266 | 422 | 197 | |
| Cost of revenues | 53 | 152 | 94 | |
| Gross profit | 213 | 270 | 103 | |
| Research and development | 1,685 | 1,426 | 1,642 | |
| Selling, general and administrative | 1,728 | 1,522 | 1,571 | |
| Total operating expenses | 3,413 | 2,948 | 3,213 | |
| Loss from operations | -3,200 | -2,678 | -3,110 | |
| Interest and dividend income, net | 113 | 133 | 106 | |
| Change in fair value of common warrant liability | -175 | 350 | -584 | |
| Total other income, net | 288 | -217 | 690 | |
| Net loss | -2,912 | -2,895 | -2,420 | |
| Net loss per share, basic | -0.08 | -0.08 | -0.08 | |
| Net loss per share, diluted | -0.08 | -0.08 | -0.08 | |
| Weighted-average shares of common stock outstanding, basic | 36,646,278 | 36,576,567 | 31,395,888 | |
| Weighted-average shares of common stock outstanding, diluted | 36,646,278 | 36,576,567 | 31,395,888 | |
RenovoRx, Inc. (RNXT)
RenovoRx, Inc. (RNXT)